CT
Citius Oncology, Inc.
CTOR · NASDAQ
$1.14 +10.68% (+$0.11)
1M +53.27%
Market Cap $94.8M
P/E Ratio -
Div. Yield -
ROE 102.98%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/S 13.35x
P/B 2.35x
P/E N/A
Growth
65 /100
Stable Book val. growth 7.35%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 53.13%
Net margin 648.32%
Op. margin 665.63%
Quality
1 /100
Poor ROIC 89.09%
ROE 102.98%
ROA 41.09%
Debt
51 /100
Moderate Debt/Equity 0.25x
Current ratio 0.73x
Int. coverage -82.99x
Stability
7 /100
Unstable Beta 3.53x
EPS volatility 69.16%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o CTOR
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Leonard L. Mazur
Employees
285
Headquarters
Cranford
Nadchodzące wydarzenia
17 GRU
Earnings
Upcoming earnings report